Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wilmington, DE, US. The stock last traded at $1.58, down 2.76% on the session, giving a market capitalisation of $221.2M. On trailing twelve-month figures it carries a trailing P/E of -3.34, a net margin of 0.0%. Its beta of 0.90 implies it has historically moved less than the broad market.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Inhibikase Therapeutics, Inc. is most often compared with the following Healthcare names: